CN106456611B - 用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂 - Google Patents

用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂 Download PDF

Info

Publication number
CN106456611B
CN106456611B CN201580024541.0A CN201580024541A CN106456611B CN 106456611 B CN106456611 B CN 106456611B CN 201580024541 A CN201580024541 A CN 201580024541A CN 106456611 B CN106456611 B CN 106456611B
Authority
CN
China
Prior art keywords
ondansetron
dose
formulation
solid oral
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580024541.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456611A (zh
Inventor
列扎·法西
吉利德·拉戴
盖伊·戈德堡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54067752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106456611(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of CN106456611A publication Critical patent/CN106456611A/zh
Application granted granted Critical
Publication of CN106456611B publication Critical patent/CN106456611B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580024541.0A 2014-03-11 2015-03-11 用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂 Expired - Fee Related CN106456611B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461951074P 2014-03-11 2014-03-11
US201461951092P 2014-03-11 2014-03-11
US201461951112P 2014-03-11 2014-03-11
US61/951,092 2014-03-11
US61/951,112 2014-03-11
US61/951,074 2014-03-11
US201462040136P 2014-08-21 2014-08-21
US62/040,136 2014-08-21
PCT/IB2015/000997 WO2015136377A2 (en) 2014-03-11 2015-03-11 Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

Publications (2)

Publication Number Publication Date
CN106456611A CN106456611A (zh) 2017-02-22
CN106456611B true CN106456611B (zh) 2021-07-20

Family

ID=54067752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024541.0A Expired - Fee Related CN106456611B (zh) 2014-03-11 2015-03-11 用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂

Country Status (17)

Country Link
US (3) US9675588B2 (enExample)
EP (1) EP3116500B1 (enExample)
JP (1) JP6461186B2 (enExample)
KR (1) KR20160132057A (enExample)
CN (1) CN106456611B (enExample)
AU (1) AU2015228545B2 (enExample)
BR (1) BR112016020877B1 (enExample)
CA (1) CA2941829C (enExample)
CL (1) CL2016002251A1 (enExample)
IL (1) IL247698B (enExample)
MX (1) MX373002B (enExample)
PH (1) PH12016501756B1 (enExample)
RU (1) RU2706708C2 (enExample)
SG (1) SG11201607511WA (enExample)
UA (1) UA121209C2 (enExample)
WO (1) WO2015136377A2 (enExample)
ZA (1) ZA201606276B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
JP7315383B2 (ja) * 2019-06-27 2023-07-26 株式会社Ｓｃｒｅｅｎホールディングス インクジェット用水性組成物及び固体製剤
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
CN105530935A (zh) * 2013-03-14 2016-04-27 红山生物医药有限公司 抗呕吐缓释固体剂型

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JP4674162B2 (ja) * 2003-11-14 2011-04-20 千寿製薬株式会社 アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
JP5433236B2 (ja) * 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
US20070190141A1 (en) 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CA2661561C (en) * 2006-08-18 2013-12-24 Evonik Operations Gmbh Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water
CN100584319C (zh) * 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004439A (es) 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
CN101568351B (zh) 2006-12-22 2012-05-30 3M创新有限公司 控制释放的组合物和方法
US20100196291A1 (en) 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110108058A1 (en) * 2009-11-11 2011-05-12 Axcelis Technologies, Inc. Method and apparatus for cleaning residue from an ion source component
CA2784587A1 (en) * 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2012028922A2 (en) * 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
US20120128730A1 (en) 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
CN105530935A (zh) * 2013-03-14 2016-04-27 红山生物医药有限公司 抗呕吐缓释固体剂型

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Evaluating outcomes associated with a discharge action plan employing single-dose home use of ondansetron in patients with acute gastroenteritis;Elizabeth Haines等;《Open Access Emergency Medicine》;20120326;第4卷;第1-4页 *

Also Published As

Publication number Publication date
EP3116500A2 (en) 2017-01-18
CA2941829A1 (en) 2015-09-17
CN106456611A (zh) 2017-02-22
MX373002B (es) 2020-04-30
US20150258029A1 (en) 2015-09-17
JP2017507966A (ja) 2017-03-23
UA121209C2 (uk) 2020-04-27
EP3116500B1 (en) 2023-09-13
JP6461186B2 (ja) 2019-01-30
PH12016501756A1 (en) 2016-11-07
BR112016020877A8 (pt) 2021-07-20
US20200253933A1 (en) 2020-08-13
KR20160132057A (ko) 2016-11-16
IL247698B (en) 2020-08-31
CA2941829C (en) 2021-11-02
PH12016501756B1 (en) 2016-11-07
RU2016139474A (ru) 2018-04-11
US10668050B2 (en) 2020-06-02
MX2016011734A (es) 2017-02-13
BR112016020877A2 (pt) 2017-08-15
SG11201607511WA (en) 2016-10-28
EP3116500A4 (en) 2017-10-25
RU2706708C2 (ru) 2019-11-20
BR112016020877B1 (pt) 2022-11-29
WO2015136377A2 (en) 2015-09-17
ZA201606276B (en) 2019-04-24
CL2016002251A1 (es) 2017-11-03
WO2015136377A3 (en) 2016-01-14
AU2015228545B2 (en) 2020-03-12
IL247698A0 (en) 2016-11-30
US20170258768A1 (en) 2017-09-14
US9675588B2 (en) 2017-06-13
AU2015228545A1 (en) 2016-09-22
RU2016139474A3 (enExample) 2018-10-26

Similar Documents

Publication Publication Date Title
CN102387802B (zh) 包含羟考酮和纳洛酮的立即释放药物组合物
TWI556840B (zh) 治療用組成物
TW200845972A (en) Pharmaceutical composition
CN108348473A (zh) 治疗人免疫缺陷病毒的治疗组合物
US20200253933A1 (en) Methods for treating diarrhea predominant irritable bowel syndrome
JP6919119B2 (ja) ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP6282676B2 (ja) 制吐作用のある徐放性固形製剤
JP2007513975A (ja) 徐放性トルセミド剤形
JP2005522467A (ja) 新規医薬製剤としてのエピナスチン、ベラドンナ及びシュードエフェドリンの組み合わせ
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
HK1232432A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
US9872838B2 (en) Raloxifene sprinkle composition
HK1232432B (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
HK40045804A (en) Antiemetic extended release solid dosage forms
TW202513072A (zh) 比替拉韋及利那卡帕韋之醫藥配方
JPWO2003075918A1 (ja) 塩酸ピルジカイニド含有錠剤（湿式）
HK40056549A (en) Therapeutic compositions for treatment of human immunodeficiency virus
CN119325372A (zh) 间苯三酚制剂和使用方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232432

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210720